Click Image To View Full Size
Advanced real-time clinical diagnostics at the point of care to help millions of people around the globe.
Vancouver, British Columbia, Canada – TheNewswire - 2 October 2023
Satisfai Health Inc., a Canada-based leading medical solutions provider specialising in artificial intelligence (AI) applications in Gastroenterology and GI Endoscopy, has entered into an exclusive development licence with Oxford University Innovation Limited (OUI). The Oxford Translational Gastroenterology Unit and Biomedical Engineering Department at the Big Data Institute have together developed a novel digital solution for the assessment of the length and area of involvement by Barrett’s Oesophagus, a precancerous condition, mostly in patients with gastroesophageal reflux.
Satisfai plans to further develop this exciting work so that it can be tested in trials and productized for clinical use. The technology to be further developed in this collaboration was initially devised and evaluated in a pilot study supported by Ludwig Cancer Research and the NIHR Oxford Biomedical Research Centre. The work was carried out by Sharib Ali, Barbara Braiden, Adam Bailey, Xin Lu, James East and Jens Rittscher. Its findings were reported in the journal Gastroenterology (DOI 10.1053/j.gastro.2021.05.059) in 2021.
Satisfai has an existing AI-based solution (Veritai) for the detection of dysplasia (precancerous change) in Barrett’s Oesophagus, and the licensing of technology from the Oxford group will provide for an even more comprehensive digital assessment and risk assignment in patients with Barrett’s. This combination will also help in any treatment planning that might involve endosurgical resection.
Satisfai will be working closely with the leading researchers, clinicians and academics at the University of Oxford to further build, develop and integrate the licensed technology into Veritai. This will broaden the range of AI products which Satisfai is bringing to market. The agreement builds on the work already done by Oxford researchers, supported by the NIHR Oxford Biomedical Research Centre, to deploy AI alongside endoscopy in Barrett’s patients and so determine those most at risk of developing cancer.
Barrett's Oesophagus is a gastrointestinal condition affecting around 150 million people globally; approximately 1 in 200 patients with Barrett’s will develop cancer each year.
Dr. James East, Consultant Gastroenterologist at Oxford University Hospitals NHS Foundation Trust and Associate Professor at the University of Oxford, said:
"Bringing Oxford technology into this collaboration will be a big step in providing a comprehensive, integrated suite of tools for the assessment and management of Barrett’s Oesophagus throughout the endoscopic workflow. I am delighted that we will enhance our ongoing research in this field with Satisfai to deliver AI supported care to NHS patients."
Dr. Jens Rittscher, Professor of Engineering Science at Oxford University and Adjunct at the Oxford Branch of the Ludwig Institute for Cancer Research, added:
"Our collaboration with Satisfai will translate this pioneering research into clinical practice to improve the screening, surveillance and outcomes for millions of Barrett’s Oesophagus patients around the globe."
Dr. Michael Byrne, Satisfai Health founder and CEO, and Clinical Professor of Medicine at the University of British Columbia in Vancouver, added:
"We are passionate about developing technology that helps doctors and their patients. We are very proud of our collaborations and partnerships which we have developed around the world with the aim of delivering precision medicine to millions of patients across a range of GI diseases. Bringing the talent and pedigree of the University of Oxford into the Satisfai ecosystem is very exciting."
ENDS
For more information or to arrange an interview, please contact:
Canada: Russell Cabeliza, Strategic Marketing Associate
russell@satisfai.health
UK: Andrea Stewart, Head of Marketing & Communications
andrea.stewart@innovation.ox.ac.uk
Notes to Editors
About Oxford University Innovation Limited
Oxford University Innovation (OUI) brings together staff, students and alumni; it harnesses colleges, faculties, departments and divisions to provide world-class research and education. OUI does this in ways which benefit society on a local, regional, national and global scale. As architects of commercial solutions, we enable the University community to maximise the global impact of Oxford’s research and expertise.
About Satisfai Health Inc.
Satisfai Health is a leading medical solutions provider specializing in AI applications for gastroenterology.
For more information
https://www.satisfai.health/products
https://www.linkedin.com/company/satisfaihealth
https://innovation.ox.ac.uk/technologies-available/
Copyright (c) 2023 TheNewswire - All rights reserved.
